264 related articles for article (PubMed ID: 28159572)
1. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
[TBL] [Abstract][Full Text] [Related]
2. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
Ohol YM; Wang Z; Kemble G; Duke G
PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.
Yee SS; Risinger AL
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279417
[TBL] [Abstract][Full Text] [Related]
5. FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
Gruslova A; McClellan B; Balinda HU; Viswanadhapalli S; Alers V; Sareddy GR; Huang T; Garcia M; deGraffenried L; Vadlamudi RK; Brenner AJ
Breast Cancer Res Treat; 2021 Jun; 187(2):375-386. PubMed ID: 33893909
[TBL] [Abstract][Full Text] [Related]
6. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo.
Wang H; Li H; Zuo M; Zhang Y; Liu H; Fang W; Chen X
Cancer Lett; 2008 Sep; 268(1):89-97. PubMed ID: 18482796
[TBL] [Abstract][Full Text] [Related]
7. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
10. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
[TBL] [Abstract][Full Text] [Related]
11. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.
Chang L; Fang S; Chen Y; Yang Z; Yuan Y; Zhang J; Ye L; Gu W
Lipids Health Dis; 2019 May; 18(1):118. PubMed ID: 31122252
[TBL] [Abstract][Full Text] [Related]
15. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules.
Field JJ; Pera B; Calvo E; Canales A; Zurwerra D; Trigili C; Rodríguez-Salarichs J; Matesanz R; Kanakkanthara A; Wakefield SJ; Singh AJ; Jiménez-Barbero J; Northcote P; Miller JH; López JA; Hamel E; Barasoain I; Altmann KH; Díaz JF
Chem Biol; 2012 Jun; 19(6):686-98. PubMed ID: 22726683
[TBL] [Abstract][Full Text] [Related]
16. EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Colbert PL; Vermeer DW; Wieking BG; Lee JH; Vermeer PD
Oncotarget; 2015 Jan; 6(2):953-68. PubMed ID: 25436983
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma.
Zhou Y; Jin G; Mi R; Zhang J; Zhang J; Xu H; Cheng S; Zhang Y; Song W; Liu F
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2447-2459. PubMed ID: 27601165
[TBL] [Abstract][Full Text] [Related]
18. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
Yan C; Wei H; Minjuan Z; Yan X; Jingyue Y; Wenchao L; Sheng H
PLoS One; 2014; 9(5):e97697. PubMed ID: 24866893
[TBL] [Abstract][Full Text] [Related]
19. Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells.
Kim M; Rejniak KA
Biophys J; 2014 Sep; 107(5):1236-1246. PubMed ID: 25185559
[TBL] [Abstract][Full Text] [Related]
20. Smoothened antagonists reverse taxane resistance in ovarian cancer.
Steg AD; Katre AA; Bevis KS; Ziebarth A; Dobbin ZC; Shah MM; Alvarez RD; Landen CN
Mol Cancer Ther; 2012 Jul; 11(7):1587-97. PubMed ID: 22553355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
